BR0206847A - Tratamento do diabete melito - Google Patents
Tratamento do diabete melitoInfo
- Publication number
- BR0206847A BR0206847A BR0206847-8A BR0206847A BR0206847A BR 0206847 A BR0206847 A BR 0206847A BR 0206847 A BR0206847 A BR 0206847A BR 0206847 A BR0206847 A BR 0206847A
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes mellitus
- treatment
- mellitus treatment
- melito
- diabete
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26608301P | 2001-02-02 | 2001-02-02 | |
| GB0106468A GB0106468D0 (en) | 2001-03-15 | 2001-03-15 | Treatment of diabetes mellitus |
| PCT/IB2002/000315 WO2002060422A2 (en) | 2001-02-02 | 2002-01-30 | Treatment of diabetes mellitus using vardenafil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206847A true BR0206847A (pt) | 2004-02-25 |
Family
ID=26245830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206847-8A BR0206847A (pt) | 2001-02-02 | 2002-01-30 | Tratamento do diabete melito |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6683080B2 (enExample) |
| EP (1) | EP1355651A2 (enExample) |
| JP (1) | JP2004527476A (enExample) |
| AU (1) | AU2002226633A1 (enExample) |
| BR (1) | BR0206847A (enExample) |
| CA (1) | CA2436576A1 (enExample) |
| MX (1) | MXPA03006936A (enExample) |
| WO (1) | WO2002060422A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020165237A1 (en) * | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| JP2005508978A (ja) * | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療 |
| US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| MXPA05009242A (es) * | 2003-03-17 | 2006-04-18 | Pfizer Prod Inc | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. |
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| WO2006074443A2 (en) * | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
| US20060235005A1 (en) * | 2005-04-14 | 2006-10-19 | Oak Labs, Corp. | Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia |
| DE102005018389A1 (de) * | 2005-04-20 | 2006-10-26 | Sanofi-Aventis Deutschland Gmbh | Azolderivate als Inhibitoren von Lipasen und Phospholipasen |
| EP1909793A2 (de) * | 2005-07-15 | 2008-04-16 | Proxomed Medizintechnik GmbH | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben |
| BRPI0716134A2 (pt) | 2006-09-07 | 2013-09-17 | Nycomed Gmbh | tratamento de combinaÇço para diabetes mellitus |
| EA021544B1 (ru) | 2007-06-04 | 2015-07-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Триарильные соединения и фармацевтические композиции, их содержащие |
| US20100120694A1 (en) * | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| JP5667985B2 (ja) * | 2008-12-12 | 2015-02-12 | ポクセル | インスリンとトリアジンの組合せ及び糖尿病を治療するためのその使用 |
| JP2013508295A (ja) | 2009-10-16 | 2013-03-07 | デューク・ユニヴァーシティ | 薬物誘発性手足症候群を治療するための組成物および方法 |
| US8637096B2 (en) | 2009-12-04 | 2014-01-28 | Curtis C. Stojan | Compositions and method for enhancing insulin activity |
| JP5842254B2 (ja) * | 2010-06-23 | 2016-01-13 | 国立大学法人九州大学 | Ｅｇｃｇまたはメチル化ｅｇｃｇとｐｄｅ阻害剤との組み合わせ |
| EP2621509A4 (en) | 2010-09-15 | 2016-08-03 | Synergy Pharmaceuticals Inc | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
| EP2804603A1 (en) * | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| HK1220696A1 (zh) | 2013-03-15 | 2017-05-12 | Bausch Health Ireland Limited | 鸟苷酸环化酶激动剂及其用途 |
| AU2014347668A1 (en) | 2013-11-05 | 2016-05-19 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1174431T3 (da) | 1997-11-12 | 2012-08-20 | Bayer Pharma AG | 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer |
| EP1070705A4 (en) * | 1998-04-06 | 2002-04-17 | Fujisawa Pharmaceutical Co | INDOLE DERIVATIVES |
| DE19944161A1 (de) * | 1999-09-15 | 2001-03-22 | Bayer Ag | Neue Kombination zur Behandlung von sexueller Dysfunktion |
| DK1088824T3 (da) * | 1999-09-30 | 2004-04-13 | Pfizer Prod Inc | Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer |
| AU2001219185A1 (en) | 2000-03-17 | 2001-10-03 | Alcon, Inc. | 2-acylaminobenzimidazole derivatives for treating glaucoma |
| AU5714601A (en) * | 2000-04-19 | 2001-10-30 | Univ Johns Hopkins | Methods for prevention and treatment of gastrointestinal disorders |
| WO2001088824A2 (en) | 2000-05-15 | 2001-11-22 | Imakit, Ltd. | Method and system for online custom footwear preparation |
| CA2419033A1 (en) * | 2000-08-11 | 2002-02-21 | Earl Michael Gibbs | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
-
2002
- 2002-01-30 US US10/060,788 patent/US6683080B2/en not_active Expired - Fee Related
- 2002-01-30 BR BR0206847-8A patent/BR0206847A/pt not_active IP Right Cessation
- 2002-01-30 CA CA002436576A patent/CA2436576A1/en not_active Abandoned
- 2002-01-30 JP JP2002560615A patent/JP2004527476A/ja not_active Withdrawn
- 2002-01-30 WO PCT/IB2002/000315 patent/WO2002060422A2/en not_active Ceased
- 2002-01-30 MX MXPA03006936A patent/MXPA03006936A/es unknown
- 2002-01-30 EP EP02716245A patent/EP1355651A2/en not_active Withdrawn
- 2002-01-30 AU AU2002226633A patent/AU2002226633A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002060422A3 (en) | 2002-10-10 |
| AU2002226633A1 (en) | 2002-08-12 |
| JP2004527476A (ja) | 2004-09-09 |
| CA2436576A1 (en) | 2002-08-08 |
| US6683080B2 (en) | 2004-01-27 |
| MXPA03006936A (es) | 2003-11-18 |
| US20020143015A1 (en) | 2002-10-03 |
| WO2002060422A2 (en) | 2002-08-08 |
| EP1355651A2 (en) | 2003-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0206847A (pt) | Tratamento do diabete melito | |
| BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR0100046A (pt) | Copolìmeros reticulados solúveis em água ou intumescìveis em água | |
| HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
| CL2004000889A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION. | |
| HUP0101158A3 (en) | Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus | |
| EG24124A (en) | Pharmaceutical compositions for the treatment of type-II diabetes mellitus | |
| BR0213358A (pt) | Uso de flibanserina | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| DE60336225D1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| BR9702200A (pt) | Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética | |
| NO20035602D0 (no) | Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer | |
| DE60202590D1 (de) | 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| NO984476L (no) | Sulfonamidsubstituerte kromaner, fremgangsmÕte for fremstilling derav, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene | |
| BR0214126A (pt) | Composiçáo farmacêutica para interferir na transmissão neuronal, preparação para o rejuvenescimento facial, e, métodos para interferir na transmissão neuronal, e na contração muscular | |
| ID21282A (id) | Senyawa-senyawa cincin beranggota-5 terpadu yang disubstitusi sulfonamida, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung senyawa tersebut | |
| DE60108354D1 (de) | 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen | |
| BR0214487A (pt) | Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes | |
| AU2002238673A1 (en) | Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof | |
| ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AU9743698A (en) | Allelic variant of human stat3 | |
| NO984475D0 (no) | Sulfonamidsubstituerte kromaner, fremgangsmÕte for fremstilling derav, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2055 DE 25/05/2010. |